

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V_{Leiden} mutation: a randomized trial

Jeanet M. Kemmeren, Ale Algra, Joost C. M. Meijers, Guido Tans, Bonno N. Bouma, Joyce Curvers, Jan Rosing, and Diederick E. Grobbee

A plausible mechanism to explain thrombotic risk differences associated with the use of second- and third-generation oral contraceptives (OCs), particularly in carriers of factor V_{Leiden}, is still lacking. In a double-blind trial, 51 women without and 35 women with factor V_{Leiden} were randomized to either a second- (30 µg ethinylestradiol/150 µg levonorgestrel) or third- (30 µg ethinylestradiol/150 µg desogestrel) generation OC. After 2 cycles of use and a wash-out of 2 cycles, the participants continued with the corresponding

progestagen-only preparation. Hemostatic variables that probe the activity of the anticoagulant protein C system were determined. Compared with levonorgestrel, desogestrel-containing OCs significantly decreased protein S and increased activated protein C (APC) resistance in both groups. OCs with desogestrel had the most pronounced effects in carriers of factor V_{Leiden}. Progestagen-only preparations caused changes of anticoagulant parameters opposite to those of combined OCs, which in a number of cases

were more pronounced with levonorgestrel. Our data show that progestagens in combined OCs counteract the thrombotic effect of the estrogen component. The higher thrombotic risk associated with third-generation OCs compared with second-generation OCs may be explained by the fact that desogestrel appeared less antithrombotic than levonorgestrel, especially in women with factor V_{Leiden}. (Blood. 2004;103:927-933)

© 2004 by The American Society of Hematology

Introduction

Epidemiologic studies clearly demonstrated an association between the use of oral contraceptives (OCs) and an increased risk of venous¹⁻³ and arterial thrombosis.⁴⁻⁶ Over the years, there have been many important changes in the composition and use of these preparations to reduce the vascular and metabolic side effects. In the early 1980s, third-generation oral contraceptives, containing the progestagens desogestrel or gestodene, were developed in an attempt to reduce the risk of cardiovascular diseases and to decrease androgenic side effects such as weight gain, acne, and adverse changes in metabolism of lipoprotein. However, in 1995 and 1996, 4 studies reported that women who used so-called third-generation oral contraceptives containing desogestrel or gestodene were at higher risk of venous thromboembolism than users of oral contraceptives with the second-generation progestagen, levonorgestrel.⁷⁻¹⁰ The absolute risk of venous thrombosis associated with the use of particularly third-generation oral contraceptives is further elevated among carriers of the factor V_{Leiden} mutation,⁹⁻¹¹ a hereditary disorder in which activated factor V is inactivated by activated protein C (APC) at a lower rate than normal factor Va.¹²⁻¹⁴ This hereditary defect, also called APC resistance, is a common risk factor for venous thrombosis, which is associated with a 3- to 7-fold increased risk in heterozygous individuals.¹²⁻¹⁴

A plausible biologic mechanism for the thrombotic effects of second- and third-generation oral contraceptives is still lacking. Rosing et al^{15,16} reported that oral contraceptive use leads to acquired APC resistance. Women using third-generation oral contraceptives were more resistant to the anticoagulant action of APC than users of second-generation oral contraceptives. Besides that, they reported that the effects of oral contraceptives and factor V_{Leiden} on the APC sensitivity ratio (a hemostatic variable that quantifies the efficacy with which APC down-regulates thrombin generation in plasma; APC-sr) were additive.¹⁵ The APC resistance test used in these studies has since then been clinically validated,¹⁷ lending support to the proposal that the more pronounced acquired APC resistance observed in users of third-generation OCs may explain why they are exposed to a higher thrombotic risk than second-generation OC users.

A recent cross-over study indicated that second- and third-generation oral contraceptives not only cause differences in acquired APC resistance, but also have different effects on a large number of other procoagulant, anticoagulant, and fibrinolytic parameters.¹⁸⁻²⁰ Particularly, the differential changes of the proteins involved in the protein C system may contribute to the thrombotic effects of oral contraceptives.¹⁸ The protein C system, which comprises the plasma proteins protein C and protein S, down-regulates in vivo blood coagulation¹⁴ via proteolytic inactivation of

From the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; the Department of Neurology and the Department of Haematology, University Medical Center Utrecht, The Netherlands; the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; and the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.

Submitted April 24, 2003; accepted September 16, 2003. Prepublished online as *Blood* First Edition Paper, October 9, 2003; DOI 10.1182/blood-2003-04-1285.

Supported by grant 98.001 from the Dutch Thrombosis Foundation. J.C.M.M. is an established investigator of the Netherlands Heart Foundation (grant D96.021)

The online version of this article contains a data supplement.

Reprints: A. Algra, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Room D.01.335, PO Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: a.algra@neuro.azu.nl.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2004 by The American Society of Hematology




Figure 1. Flow diagram of the participants.

coagulation factor Va and VIIIa. Protein S, which acts as cofactor of APC, also exhibits anticoagulant activity independent of APC by directly inhibiting thrombin formation.¹⁵ The anticoagulant activity of protein S is modulated by C4b-binding protein, which binds some 60% of plasma protein S.^{16,18} The physiologic importance of the protein C system is illustrated by the fact that defects in this pathway are associated with an increased risk of venous thromboembolism.²¹⁻²³ The thrombotic risk of women with hereditary defects in the protein C pathway is enhanced by oral contraceptive use.¹¹

For a long time, the increased thrombotic risk associated with oral contraceptive use was attributed to the estrogen component. Because low-dose second- and third-generation oral contraceptives contain the same estrogen dose, the differences may reflect a

progestagen-specific effect. Although it has been proposed that progestagens have estrogen-like effects,²⁴ among others on hemostasis,²⁵ there are as yet no data on the influence of levonorgestrel or desogestrel in the absence of the estrogen component on the protein C pathway.

To gain more insight in the biologic basis of an enhanced risk of venous thrombosis in oral contraceptive users, particularly in carriers of factor V_{Leiden}, we performed a double-blind randomized trial in which we determined the effects of second- and third-generation progestagens, alone or in combination with estrogens, on the protein C pathway in the absence or presence of the factor V_{Leiden} mutation.

Patients, materials, and methods

Study design and participants

Figure 1 shows the flow of the participants during the study. In 1998, 1083 female students and employees of Utrecht University aged 18 to 40 years were screened for the presence of the factor V_{Leiden} mutation. Of the women, 60 (5.5%) were heterozygous carriers of the factor V_{Leiden} mutation. These women and 111 women without factor V_{Leiden} were approached for the trial; 36 women with and 51 women without V_{Leiden} agreed to participate and were tested whether or not they met the exclusion criteria. Exclusion criteria included the following: a history of any malignant disorder; cardiovascular, cerebrovascular, hepatic or renal diseases; venous thrombosis; epilepsy or classical migraine; vaginal bleeding of unknown etiology; pregnancy; rheumatoid arthritis; diabetes mellitus; psychiatric disorders; alcohol abuse or drug abuse within the last 12 months; heavy smoking; excessive obesity; chronic infectious diseases; and any other serious disease. Moreover, volunteers with a contraindication to estrogens and/or progestagens were excluded. One woman with V_{Leiden} was excluded because of a psychiatric disorder. From the women without factor V_{Leiden} no one met the exclusion criteria.

One participant was excluded from phase 2 because the wrong medication was supplied. Another woman withdrew consent in phase 2 because of side effects of the progestagen-only pill (symptoms of depression). Both were factor V_{Leiden}-negative. The trial started in January 1999 and ended in October 1999.

Figure 2 illustrates the design of the trial. Women with and without factor V_{Leiden} were randomly assigned to 1 of 2 different combination pills containing either 30 µg ethinylestradiol and 150 µg levonorgestrel or 30 µg ethinylestradiol and 150 µg desogestrel. These formulations are identical to those commercially marketed. The oral contraceptives were




Figure 2. Trial profile. *Desogestrel-containing OCs, 30 µg ethinylestradiol + 150 µg desogestrel; levonorgestrel-containing OCs, 30 µg ethinylestradiol + 150 µg levonorgestrel; desogestrel only, 150 µg desogestrel; and levonorgestrel only, 150 µg levonorgestrel. X indicates blood sampling. → indicates comparisons described in the tables. Comparisons referring to Tables 2-3 are also made for women with the factor V_{Leiden} mutation.

used for a period of 2 menstruation cycles (phase 1). After a wash-out of 2 menstrual periods, the participants were treated with a corresponding progestagen-only preparation containing either 150 µg levonorgestrel or 150 µg desogestrel. These progestagens were used for a period of 2 menstruation cycles without a stop week to provide full contraceptive safety (phase 2). The study medication was labeled in blocks of 10 according to a randomization list generated by the medication manufacturer. Participants were enrolled and assigned to their groups by the investigators. Participants, those administering the intervention, and those assessing the outcomes were not aware of group assignment. There were 2 blood samples taken at the end of phase 1 (days 47 ± 2 and 49 ± 2), at the end of the wash-out period (days 101 ± 2 and 105 ± 2), and at the end of phase 2 (days 152 ± 2 and 154 ± 2). We used duplicate sampling to reduce random measurement error. For reasons of safety, ultrasound examination of the veins of both legs was performed before the start of the study, after the wash-out period, and at the end of phase 2, to exclude venous thrombosis.

A power calculation showed that if 25 women were allocated in each treatment group, assuming an APC-sr of $380 \text{ nM/minute} \pm 50$ in healthy individuals, a differences in APC-sr of 40 nM/minute or more could be detected ($\alpha = 0.05$; $\beta = 0.20$). This difference is enough to achieve statistical significance in the APC-sr calculation. With this sample size, we also expected to be able to demonstrate differences in the other hemostatic variables.

Before start of the study, all selected women were informed about the aims and potential risks of the study. All participants gave written informed consent. The study was approved by the Ethics Committee of the University Medical Center Utrecht.

Laboratory methods

All blood samples were drawn in the morning after an overnight abstinence from intake of food, caffeine, alcohol, or nicotine. Cell-free, citrated plasma was prepared and centrally stored at -80°C . Anticoagulant parameters were determined after all participants had completed the treatment regimen and were done in duplicate.

All commercially available assays were carried out according to the manufacturer's instructions. Protein C was determined using the Coamatic protein C activity kit from Chromogenix (Mölnådal, Sweden). Total protein S antigen was assayed by an enzyme-linked immunosorbent assay (ELISA) using antibodies from DAKO (Glostrup, Denmark). Free protein S was measured by precipitating the C4b-binding protein-bound fraction with polyethylene glycol 8000 and measuring the concentration of free protein S in the supernatant. C4b-binding protein antigen levels were determined by enzyme-linked immunosorbent assay using a combination of monoclonal antibodies against C4b-binding protein (8C11 and horseradish peroxidase-labeled 9H10). The APC-independent anticoagulant activity of protein S (PS_{APCind}) was determined as described by van Wijnen et al²⁶ with 2 modifications. To avoid contamination with endogenous phospholipids, all plasma samples were centrifuged for 10 minutes at $13\,000g$ at 20°C . Plasma aliquots taken from the bottom of the tube were used for the assay. Recombinant human tissue (Innovin; Dade Behring, Marburg, Germany) diluted 100-fold was used to initiate coagulation. Antigen levels of protein C inhibitor (PCI) were determined by ELISA using a monoclonal antibody against PCI (API-93) as capturing antibody and rabbit polyclonal anti-PCI

serum as secondary antibody.²⁷ APC sensitivity ratios (APC-sr) were determined by quantifying the effect of APC on thrombin generation as described before.¹⁸ The plasma levels of the proteins determined (antigen or activity) were expressed as percentage of that present in normal pooled plasma determined in the same experiment. The presence of the factor V_{Leiden} mutation was assessed by DNA analysis.²⁸

All tests were performed without knowledge of the carrier status of the individual and the oral contraceptive preparation used.

Statistical analysis

To reduce random measurement error, the results of the 2 visits at the end of phase 1, the wash-out period, and phase 2 were averaged. If only one sample was available, the values obtained for that sample were used in the analysis.

According to the design of the trial (Figure 1), 3 comparisons were made in the data analysis and represented in the corresponding tables. To assess the effect of progestagens in combined oral contraceptives, mean differences in anticoagulant parameters between the 2 treatment groups relative to values when no oral contraceptives were used were tested with unpaired *t* tests for noncarriers and carriers of factor V_{Leiden} separately.

The effect of combined oral contraceptives (progestagens plus estrogen) versus progestagen-only preparations was calculated by testing differences in means between phase 1 and phase 2 using paired *t* tests. Again, these analyses were performed separately for noncarriers and carriers of factor V_{Leiden}.

Differential effects of a hormone preparation between women with and without the factor V_{Leiden} mutation were assessed from the mean change in anticoagulant parameters in the period of oral contraceptive use relative to no use using unpaired *t* tests.

For all estimates 95% confidence intervals were calculated.

In addition to the parametric *t* tests we also performed nonparametric tests, which yielded similar results to the parametric ones.

Results

Characteristics of the volunteers participating in the study

No clinically relevant differences in general characteristics were present between the study groups (Table 1). The values of the anticoagulant parameters determined at the various stages in the trial are summarized in Table 2. During the study none of the volunteers showed clinical signs or symptoms of venous thromboembolism or abnormalities on ultrasound examination of the leg veins.

Effect of combined oral contraceptives

Women without factor V_{Leiden} who used desogestrel-containing oral contraceptives became significantly more resistant to APC (as indicated by the increase of the APC-sr) than users of levonorgestrel-containing oral contraceptives (mean difference in change: 0.38; 95% CI, 0.08 to 0.67) (Table 2; Figure 3). In noncarriers of factor

Table 1. Baseline characteristics according to factor V_{Leiden} and type of oral contraceptive (OC)

Characteristic	Factor V _{Leiden} -negative		Factor V _{Leiden} -positive	
	Levonorgestrel-containing OC, n = 24	Desogestrel-containing OC, n = 27	Levonorgestrel-containing OC, n = 19	Desogestrel-containing OC, n = 16
Age, y	22.9 ± 3.4	24.1 ± 5.9	23.3 ± 2.7	22.6 ± 2.8
Body weight, kg	67.6 ± 10.6	67.6 ± 9.5	64.0 ± 7.9	65.9 ± 10.6
Height, cm	168.6 ± 5.5	170.9 ± 6.5	169.2 ± 6.4	171.5 ± 6.7
BMI, kg/m ²	23.4 ± 3.4	23.2 ± 3.4	22.3 ± 2.5	22.4 ± 3.5
Previous OC use	19 (79)	20 (74)	15 (79)	15 (94)
Second generation	5 (26)	9 (45)	6 (40)	3 (20)
Third generation	13 (68)	5 (25)	9 (60)	5 (33)
Others	1 (5)	6 (30)	0	7 (47)

Values are means ± SD or numbers with percentage in parentheses. BMI indicates body mass index.

Table 2. Effects of combined oral contraceptives (OCs) and progestagen-only preparations on anticoagulant parameters in the absence or presence of the factor V_{Leiden} mutation

	Levonorgestrel-containing OC		Desogestrel-containing OC		Mean difference in change (95% CI)	Levonorgestrel only		Desogestrel only		Mean difference in change (95% CI)‡
	No use, mean ± SD	OC use, mean ± SD	No use, mean ± SD	OC use, mean ± SD		No use,† mean ± SD	OC use, mean ± SD	No use, mean ± SD	OC use, mean ± SD	
Factor V_{Leiden}-negative										
Protein C	96.0 ± 18.3	108.8 ± 21.7	92.0 ± 14.0	103.7 ± 17.8	-1.1 (-7.2 to 5.0)	96.7 ± 18.3	92.7 ± 18.6	92.0 ± 14.0	84.9 ± 11.5	-3.1 (-6.8 to 0.6)
Protein S total	88.5 ± 13.2	83.4 ± 13.6	85.9 ± 9.9	71.7 ± 10.2	-9.1 (-13.4 to -4.7)	88.6 ± 13.4	94.9 ± 13.4	85.9 ± 9.9	92.5 ± 13.2	0.3 (-4.2 to 4.7)
Protein S free	39.9 ± 7.0	43.9 ± 8.0	38.9 ± 5.8	33.8 ± 7.5	-9.2 (-12.0 to -6.4)	40.0 ± 7.1	47.9 ± 8.4	38.9 ± 5.8	42.7 ± 7.1	-4.0 (-6.4 to -1.7)
C4BP	89.9 ± 20.1	77.1 ± 17.3	88.8 ± 15.8	79.1 ± 15.1	2.6 (-1.5 to 6.6)	89.2 ± 20.3	82.0 ± 15.8	88.8 ± 15.8	87.5 ± 17.8	6.0 (0.03 to 12.0)
PS _{APCind}	1.32 ± 0.12	1.19 ± 0.08	1.34 ± 0.13	1.14 ± 0.07	-0.08 (-0.13 to -0.02)	1.32 ± 0.12	1.46 ± 0.23	1.34 ± 0.13	1.35 ± 0.13	-0.13 (-0.20 to -0.06)
PCI	90.6 ± 16.6	101.0 ± 15.0	90.5 ± 13.7	99.5 ± 18.1	-1.4 (-8.4 to 5.6)	88.9 ± 14.6	90.4 ± 17.7	90.5 ± 13.7	90.0 ± 14.4	-2.0 (-7.8 to 3.9)
APC-sr	1.92 ± 0.61	3.26 ± 0.72	2.04 ± 0.63	3.76 ± 0.77	0.38 (0.08 to 0.67)	1.93 ± 0.63	1.58 ± 0.61	2.04 ± 0.63	1.80 ± 0.52	0.11 (-0.09 to 0.30)
Factor V_{Leiden}-positive										
Protein C	92.1 ± 12.3	102.5 ± 16.3	106.6 ± 15.9	122.7 ± 22.2	5.7 (-1.8 to 13.3)	92.1 ± 12.3	86.2 ± 11.1	106.6 ± 15.9	96.5 ± 14.9	-4.2 (-9.0 to 0.7)
Protein S total	88.2 ± 11.4	85.9 ± 12.9	96.9 ± 10.9	77.6 ± 11.1	-16.9 (-23.8 to -10.1)	88.2 ± 11.4	95.2 ± 10.5	96.9 ± 10.9	100.6 ± 11.2	-3.2 (-8.1 to 1.6)
Protein S free	42.2 ± 9.4	45.9 ± 9.9	42.1 ± 8.1	35.3 ± 8.4	-10.5 (-15.0 to -5.9)	42.2 ± 9.4	48.9 ± 7.8	42.1 ± 8.1	45.9 ± 6.8	-2.9 (-5.9 to 0.1)
C4BP	80.5 ± 11.2	72.3 ± 9.8	101.5 ± 12.7	85.4 ± 16.6	-8.0 (-13.9 to -2.1)	80.5 ± 11.2	75.1 ± 9.7	101.5 ± 12.7	95.3 ± 12.1	-0.8 (-6.4 to 4.9)
PS _{APCind}	1.24 ± 0.10	1.16 ± 0.10	1.33 ± 0.12	1.14 ± 0.05	-0.10 (-0.15 to -0.05)	1.24 ± 0.10	1.33 ± 0.16	1.33 ± 0.12	1.33 ± 0.10	-0.09 (-0.14 to -0.03)
PCI	86.0 ± 14.9	92.2 ± 16.3	92.5 ± 17.0	106.9 ± 17.6	8.2 (2.2 to 14.1)	86.0 ± 14.9	85.7 ± 18.3	92.5 ± 17.0	91.0 ± 20.8	-0.6 (-8.0 to 6.8)
APC-sr	4.60 ± 1.02	5.95 ± 1.38	4.29 ± 1.00	7.06 ± 1.40	1.41 (0.76 to 2.07)	4.60 ± 1.02	4.09 ± 0.97	4.29 ± 1.00	4.10 ± 1.04	0.32 (-0.05 to 0.68)

The individual plasma components are expressed as percent of normal pooled plasma. PCI indicates protein C inhibitor; APC-sr, activated protein C sensitivity ratio; C4BP, C4b-binding protein; and PS_{APCind}, APC-independent anticoagulant activity of protein S.

*Formula: (no use of levonorgestrel containing OC - use of levonorgestrel containing OC) - (no use of desogestrel containing OC - use of desogestrel containing OC).

†For this analysis, one woman was excluded due to protocol violation in phase 2.

‡Formula: (no use of levonorgestrel - use of levonorgestrel) - (no use of desogestrel - use of desogestrel).

V_{Leiden}, the use of levonorgestrel- and desogestrel-containing oral contraceptives also caused significant differential changes of total protein S (-9.1; 95% CI, -13.4 to -4.7), free protein S (-9.2; 95% CI, -12.0 to -6.4), and protein S_{APCind} (-0.08; 95% CI,

-0.13 to -0.02). No differential changes were observed for protein C, C4b-binding protein, and protein C inhibitor.

In carriers of factor V_{Leiden}, the use of desogestrel- and levonorgestrel-containing oral contraceptives had significant differential effects on all anticoagulant parameters, except for protein C (Table 2; Figure 4A).

Effect of progestagen-only preparations

The changes observed in noncarriers of factor V_{Leiden} were significantly less pronounced on desogestrel than on levonorgestrel for the increase of free protein S (-4.0; 95% CI, -6.4 to -1.7) and PS_{APCind} (-0.13; 95% CI, -0.20 to -0.06) and the decrease in C4b-binding protein (6.0; 95% CI, 0.03-12.0) (Table 2; Figure 4B). In carriers of factor V_{Leiden} the only significant differential effect between levonorgestrel and desogestrel was observed for PS_{APCind} (-0.09; 95% CI, -0.14 to -0.03).

The effects of the combination of estrogens and progestagens versus progestagen-only were estimated from the difference between the anticoagulant parameters in phase 1 and phase 2 (see Supplemental Table S1 on the *Blood* website; click on the "Data Set" link at the top of the online article). Except for free protein S




Figure 3. APC-sr levels (95% CI) on combined oral contraceptives (OCs), progestagen-only (POP), or during no oral contraceptive use according to the absence or presence of the factor V_{Leiden} mutation. Error bar with open square indicates no oral contraceptive use; error bar with star, oral contraceptive use (end phase 1); and error bar with black square, POP use (end phase 2).




Figure 4. Changes of anticoagulant parameters during the study according to pill type and presence of the factor V_{Leiden} mutation. PS indicates protein S; C4BP, C4b-binding protein; PS_{APCind}, APC-independent anticoagulant activity of protein S; PCI, protein C inhibitor; and APC-sr, activated protein C sensitivity ratio.

and C4b-binding protein in carriers of factor V_{Leiden} , all anticoagulant parameters differed significantly between phases 1 and 2.

Comparison of women with and without the factor V_{Leiden} mutation

During the use of levonorgestrel-containing oral contraceptives a significantly more pronounced decrease was found in noncarriers than in carriers for C4b-binding protein and PS_{APCind} (Supplemental Table S2). In contrast, the changes observed during the use of desogestrel-containing oral contraceptives were more pronounced in carriers than in noncarriers of factor V_{Leiden} , which was statistically significant for the increase in the APC-sr (Figure 3) and the decrease in the plasma level of C4b-binding protein.

Discussion

Oral contraceptive use has repeatedly been associated with an increased risk of venous thrombosis.¹⁻³ Particularly, the differential changes of the proteins involved in the protein C system may contribute to the thrombotic effects of oral contraceptives. In the present study, we found that third-generation oral contraceptives have a stronger effect on anticoagulant parameters than second-generation preparations. These effects were not found with the progestagen components of these pills only. On the contrary, the effects of progestagen-only preparations were in general more

pronounced with levonorgestrel compared with desogestrel. Our findings suggest that, compared with levonorgestrel, desogestrel is less effective in counteracting the thrombotic effects induced by the estrogen component in combined oral contraceptives.

Despite the small number of women with factor V_{Leiden} , which may have led to less precise estimates, we showed that earlier reported changes in anticoagulant parameters induced by oral contraceptives in healthy women^{18,29,30} also occurred in women with factor V_{Leiden} .^{18,29} In carriers as well as in noncarriers of the factor V_{Leiden} mutation both oral contraceptives induced APC resistance, increased the plasma levels of protein C and protein C inhibitor, and decreased the APC-independent anticoagulant activity of protein S and the plasma levels of total protein S and C4b-binding protein. In both study populations, free protein S increased on levonorgestrel- and decreased on desogestrel-containing oral contraceptives. This increase of free protein S on combined pills with levonorgestrel is explained by the fact that on this contraceptive total protein S hardly changes, which, together with the decrease of C4b-binding protein (which complexes protein S), results in an elevation of the plasma level of free protein S. In both carriers and noncarriers of factor V_{Leiden} the changes in anticoagulant parameters were most pronounced in the women using desogestrel-containing oral contraceptives.

Since hereditary defects of the protein C pathway are associated with an increased risk of venous thromboembolism,²¹⁻²³ the differential effects of levonorgestrel- and desogestrel-containing oral contraceptives particularly on the plasma levels of protein S and on the degree of acquired APC resistance may well explain the differences in thrombotic risk associated with these preparations.^{7,8,10,31} Although the effects of third-generation OCs on the plasma levels of total and free protein S is relatively small, it should be emphasized that these concern mean changes and that in some individuals the changes are larger than the mean. Thus, it is possible that in a woman with a low protein S at baseline, a change in protein S larger than the mean may further disturb the hemostatic balance and increase the thrombotic risk.³²

With respect to the clinical relevance of acquired APC resistance, it was recently demonstrated that APC-sr determined with the APC resistance test used in this study predicts for venous thrombosis, in men and in women both in the absence and presence of the factor V_{Leiden} mutation.¹⁷ This means that acquired APC resistance may well explain the occurrence of venous thrombosis and different thrombotic risks in OC users. Moreover, the pronounced increase in APC resistance in women with factor V_{Leiden} who use desogestrel-containing oral contraceptives may account for the reported elevated risk of venous thrombosis in carriers of this mutation taking third-generation oral contraceptives.⁹

To determine to what extent the progestagens levonorgestrel and desogestrel are responsible for the changes of anticoagulant parameters induced by combined oral contraceptives, we also investigated the effect of progestagen-only pills on the protein C pathway. Some years ago, Egberg et al³³ studied 2 long-term contraceptive implants (containing the biologically active metabolite of desogestrel or levonorgestrel) with respect to hemostatic variables. They found that both implants had similar small effects on hemostasis. Winkler et al³⁴ compared 2 progestagen-only pills containing either 30 μ g levonorgestrel or 75 μ g desogestrel. They reported increased protein S levels for desogestrel compared with levonorgestrel. However, the doses of progestagen used in these pills differed from those normally used in oral contraceptives. In

our study we compared progestagen-only preparations that contained the same dose of progestagen as present in oral contraceptives (150 µg levonorgestrel or desogestrel). Almost all effects of combined oral contraceptives on anticoagulant parameters disappeared or even went in an opposite direction when the participants used progestagen-only preparations. Our observations are supported by reports indicating that the changes of several other hemostatic parameters on progestagen-only pills and implants are the inverse of those induced by combined oral contraceptives,^{33,34} which may indicate a net antithrombotic effect. Progestagen-only pills may thus be a safer method of contraception. However, during the study many women complained about irregular bleedings when these preparations were used (65% compared with 15% during the use of combined oral contraceptives).

The present study may provide an explanation for the observation that combined oral contraceptives with desogestrel cause more marked changes of the anticoagulant protein C system than levonorgestrel-containing oral contraceptives. We assume that estrogens such as ethinylloestradiol cause changes of anticoagulant parameters that are in the same direction, but more profound than observed with combined oral contraceptives. Due to their androgenic properties, progestagens induce changes in the anticoagulant system that are opposite to those of estrogen and that, due to the higher androgenicity,^{35,36} are more pronounced with levonorgestrel than with desogestrel. Hence, we propose that combined oral contraceptives with desogestrel induce more profound changes of the anticoagulant system than levonorgestrel-containing oral contra-

ceptives because the effects of ethinylloestradiol on anticoagulant parameters are less well compensated by desogestrel than by levonorgestrel. This view is supported by the observation that APC resistance correlates inversely with the dose of levonorgestrel present in 5 different combined oral contraceptives,³⁷ suggesting that high concentrations of levonorgestrel counteract the increase in APC resistance.

In conclusion, our findings indicate that desogestrel-containing oral contraceptives have a more pronounced effect on the anticoagulant protein C system than levonorgestrel-containing oral contraceptives, especially in women with factor V_{Leiden}. Particularly the decrease in protein S and the profoundly increased resistance to APC might contribute to the elevated risk of venous thrombosis in carriers of factor V_{Leiden} who use third-generation oral contraceptives. The differential effects of second- and third-generation oral contraceptives on the anticoagulant pathway can at least be partially explained by the observation that levonorgestrel is more effective than desogestrel in counteracting the thrombotic effect of ethinylloestradiol.

Acknowledgments

We thank all participants who took part in this study. We are indebted to Esther van Lunteren for her help in the execution of this study and to Winnie Tekelenburg and Stella Thomassen for laboratory analysis.

References

- Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. *BMJ*. 1970;2:203-209.
- Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. *Am J Obstet Gynecol*. 1990; 163:396-403.
- Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). *N Engl J Med*. 1981;305:612-618.
- Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. *BMJ*. 1989;298:165-168.
- La Vecchia C, Franceschi S, Decarli A, Pampalona S, Tognoni G. Risk factors for myocardial infarction in young women. *Am J Epidemiol*. 1987;125:832-843.
- Stolley PD, Strom BL, Sartwell PE. Oral contraceptives and vascular disease. *Epidemiol Rev*. 1989;11:241-243.
- World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. *Lancet*. 1995;346: 1582-1588.
- Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet*. 1995;346:1589-1593.
- Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V_{Leiden} mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. *Lancet*. 1995;346:1593-1596.
- Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study: Transnational Research Group on Oral Contraceptives and the Health of Young Women. *BMJ*. 1996;312:83-88.
- Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V_{Leiden} mutation. *Lancet*. 1994;344:1453-1457.
- Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. *J Biol Chem*. 1995;270:21158-21166.
- Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. *J Biol Chem*. 1995;270:4053-4057.
- Aparicio C, Dahlback B. Molecular mechanisms of activated protein C resistance: properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. *Biochem J*. 1996;313(pt 2):467-472.
- Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. *Br J Haematol*. 1997;97:233-238.
- Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. *Lancet*. 1999;354:2036-2040.
- Tans G, Van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. *Br J Haematol*. 2003;122:465-470.
- Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. *Thromb Haemost*. 2000;84:15-21.
- Meijers JC, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. *Thromb Haemost*. 2000;84:9-14.
- Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. *Thromb Haemost*. 2000; 84:4-8.
- Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. *N Engl J Med*. 1984;311:1525-1528.
- Bertina RM. Molecular risk factors for thrombosis. *Thromb Haemost*. 1999;82:601-609.
- Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. *Am J Obstet Gynecol*. 1992; 167:1184-1191.
- Lemus AE, Zaga V, Santillan R, et al. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. *J Endocrinol* 2000;165:693-702.
- Kuhl H. Pharmacokinetics of oestrogens and progestogens. *Maturitas*. 1990;12:171-197.
- van Wijnen M, van 't Veer C, Meijers JC, Bertina RM, Bouma BN. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. *Thromb Haemost*. 1998;80: 930-935.
- Elisen MG, Maseland MH, Church FC, Bouma BN, Meijers JC. Role of the A+ helix in heparin binding to protein C inhibitor. *Thromb Haemost*. 1996;75:760-766.
- Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. *Lancet*. 1994;343:1535-1536.
- Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating

- thrombomodulin during use of oral contraceptives. *Thromb Haemost*. 1996;76:729-734.
30. Boeger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and gender affect protein S status. *Blood*. 1987;69:692-694.
31. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. *Arch Intern Med*. 1999;159:65-70.
32. Tans G, Bouma BN, Buller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. *Sem Vasc Med*. 2003;3:61-68.
33. Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant: a prospective randomized clinical trial. *Contraception*. 1998;58:93-98.
34. Winkler UH, Howie H, Buhler K, Korver T, Geurts TB, Coelingh BH. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. *Contraception*. 1998;57:385-392.
35. Bergink EW, Holma P, Pyorala T. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. *Scand J Clin Lab Invest*. 1981;41:663-668.
36. McClamrock HD, Adashi EY. Pharmacokinetics of desogestrel. *Am J Obstet Gynecol*. 1993;168:1021-1028.
37. Kluff C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. *Lancet*. 1999;354:832-833.